These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1525702)

  • 1. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose, long-term effects of prednisone versus deflazacort.
    Olgaard K; Storm T; van Wowern N; Daugaard H; Egfjord M; Lewin E; Brandi L
    Calcif Tissue Int; 1992 Jun; 50(6):490-7. PubMed ID: 1525702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.
    Broyer M; Terzi F; Lehnert A; Gagnadoux MF; Guest G; Niaudet P
    Pediatr Nephrol; 1997 Aug; 11(4):418-22. PubMed ID: 9260237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term efficacy and safety of two different corticosteroids in chronic sarcoidosis.
    Rizzato G; Riboldi A; Imbimbo B; Torresin A; Milani S
    Respir Med; 1997 Sep; 91(8):449-60. PubMed ID: 9338047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dependent effects of deflazacort and prednisone on growth and skeletal maturation.
    Aicardi G; Benso L; Vignolo M; Terragna A; Verrina E; Cordone G; Coppo R; Sernia O; Sardella ML; Di Battista E
    Br J Rheumatol; 1993 May; 32 Suppl 2():39-43. PubMed ID: 8495279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deflazacort in juvenile chronic arthritis.
    Loftus JK; Reeve J; Hesp R; David J; Ansell BM; Woo PM
    J Rheumatol Suppl; 1993 Apr; 37():40-2. PubMed ID: 8501751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
    J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid-induced mandibular bone loss in relation to marginal periodontal changes.
    von Wowern N; Klausen B; Olgaard K
    J Clin Periodontol; 1992 Mar; 19(3):182-6. PubMed ID: 1556246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of glucocorticoids on calcium absorption and bone mass.
    Gennari C
    Br J Rheumatol; 1993 May; 32 Suppl 2():11-4. PubMed ID: 8495275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A histomorphometric long-term longitudinal study of trabecular bone loss in glucocorticoid-treated patients: prednisone versus deflazacort.
    LoCascio V; Ballanti P; Milani S; Bertoldo F; LoCascio C; Zanolin EM; Bonucci E
    Calcif Tissue Int; 1998 Mar; 62(3):199-204. PubMed ID: 9501951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potency ratio--a brief synopsis.
    Avioli LV
    Br J Rheumatol; 1993 May; 32 Suppl 2():24-6. PubMed ID: 8495276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases.
    Scudeletti M; Puppo F; Lanza L; Mantovani L; Bosco O; Iudice A; Imbimbo B; Indiveri F
    Eur J Clin Pharmacol; 1993; 45 Suppl 1():S29-34. PubMed ID: 8313931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of prednisone and deflazacort on vertebral bone mass.
    Gennari C; Imbimbo B
    Calcif Tissue Int; 1985 Dec; 37(6):592-3. PubMed ID: 3937579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bone loss during low dose glucocorticoid treatment in patients with polymyalgia rheumatica. A double-blind, prospective comparison between prednisolone and deflazacort].
    Krogsgaard MR; Thamsborg G; Lund B
    Ugeskr Laeger; 1997 Jul; 159(30):4641-4. PubMed ID: 9245040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis.
    Messina OD; Barreira JC; Zanchetta JR; Maldonado-Cocco JA; Bogado CE; Sebastián ON; Flores D; Riopedre AM; Redondo G; Lázaro A
    J Rheumatol; 1992 Oct; 19(10):1520-6. PubMed ID: 1464862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are children with idiopathic nephrotic syndrome at risk for metabolic bone disease?
    Gulati S; Godbole M; Singh U; Gulati K; Srivastava A
    Am J Kidney Dis; 2003 Jun; 41(6):1163-9. PubMed ID: 12776267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interim long-term analysis.
    Aicardi G; Milani S; Imbimbo B; Vignolo M; Di Battista E; Gusmano R; Terragna A; Cordone G; Cottafava F; Coppo R
    Calcif Tissue Int; 1991 Apr; 48(4):283-7. PubMed ID: 2059880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort.
    Loftus J; Allen R; Hesp R; David J; Reid DM; Wright DJ; Green JR; Reeve J; Ansell BM; Woo PM
    Pediatrics; 1991 Sep; 88(3):428-36. PubMed ID: 1881719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
    Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
    Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
    Saviola G; Abdi Ali L; Shams Eddin S; Coppini A; Cavalieri F; Campostrini L; Sacco S; Bucci M; Cirino G; Rossini M
    Rheumatology (Oxford); 2007 Jun; 46(6):994-8. PubMed ID: 17384176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deflazacort induced stronger immunosuppression than expected.
    Gonzalez-Castañeda RE; Castellanos-Alvarado EA; Flores-Marquez MR; Gonzalez-Perez O; Luquin S; Garcia-Estrada J; Ramos-Remus C
    Clin Rheumatol; 2007 Jun; 26(6):935-40. PubMed ID: 16738843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.